StoneWise
望石智慧
elsewhere's corpus does not cover StoneWise as a subject in its own right. The only material that names the company appears in background references where it is mentioned as a portfolio holding of Heart Capital (心资本) and Linear Capital (线性资本), described as an "AI-driven drug R&D company" (AI驱动药物研发公司) that received Series B investment from Heart Capital . Linear Capital also listed it among its portfolio companies recognized at a 2023 ChinaVenture award , and it appeared among Linear's exhibitor companies at WAIC 2026 . No document chunks are actually about StoneWise itself, so elsewhere cannot provide a substantive profile of its business, team, or technology.
AI-generated — may contain errors, please verify.
Coverage
The Start of Autumn — Wanwu Awaits the Harvest | Linear Quarterly
Spring sows, summer grows — the answer is on its way.
At the Tail End of WAIC, Archiving a Tech Summer of Storms and Spectatorship | Linear News
Those moments that happened inside and outside the exhibition hall.
Spring has arrived — can blossoms be far behind? | Linear Quarterly
Rather than waiting for spring, define it.
The First Newsletter of Autumn | Linear Quarterly
Cycles turn, and Wanwu Capital begins to harvest.
Linear Capital | Linear Path, Nonlinear Growth
Striving to become China's best frontier technology and innovation fund.
Linear Capital received honors including "Top 8 Best Early-Stage VC Firms" and "Best Investment Firm in China's AI and Big Data Industry" from ChinaVenture.
On May 19, ChinaVenture released its 2022 annual rankings of Chinese venture capital and private equity investment institutions — the ChinaVenture Awards. **Linear Capital was named among the "Top 8 Best Early-Stage VC Firms in China" and received the "Top 20 Best Investment Firms in China's AI and Big Data Sector" award, among other honors**.
